ABIONYX Pharma SA (ABNX.PA)
EUR 1.24
(2.15%)
EUR 1.24
(2.15%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.12 EUR | 20.0% |
| 2022 | -0.15 EUR | 34.78% |
| 2021 | -0.23 EUR | -174.46% |
| 2020 | -0.08 EUR | -193.32% |
| 2019 | 0.09 EUR | 128.06% |
| 2018 | -0.32 EUR | -18.52% |
| 2017 | -0.27 EUR | 80.58% |
| 2016 | -1.39 EUR | -39.0% |
| 2015 | -1.00 EUR | -100.0% |
| 2014 | -0.50 EUR | 15.25% |
| 2013 | -0.59 EUR | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.06 EUR | 0.0% |
| 2023 Q4 | -0.02 EUR | 0.0% |
| 2023 FY | - EUR | 20.0% |
| 2023 Q1 | -0.04 EUR | 32.77% |
| 2023 Q2 | -0.08 EUR | -99.75% |
| 2023 Q3 | -0.02 EUR | 73.32% |
| 2022 Q3 | -0.03 EUR | 67.86% |
| 2022 Q2 | -0.09 EUR | -101.53% |
| 2022 Q1 | -0.05 EUR | 64.85% |
| 2022 Q4 | -0.06 EUR | -98.99% |
| 2022 FY | - EUR | 34.78% |
| 2021 Q2 | -0.10 EUR | -93.42% |
| 2021 Q3 | -0.07 EUR | 34.8% |
| 2021 Q4 | -0.13 EUR | -99.39% |
| 2021 FY | - EUR | -174.46% |
| 2021 Q1 | -0.05 EUR | -25.18% |
| 2020 FY | - EUR | -193.32% |
| 2020 Q4 | -0.04 EUR | -97.61% |
| 2020 Q3 | -0.02 EUR | 50.82% |
| 2020 Q2 | -0.04 EUR | -102.38% |
| 2020 Q1 | -0.02 EUR | 56.61% |
| 2019 FY | - EUR | 128.06% |
| 2019 Q1 | 0.08 EUR | 197.28% |
| 2019 Q4 | -0.05 EUR | -103.36% |
| 2019 Q2 | 0.15 EUR | 100.0% |
| 2019 Q3 | -0.02 EUR | -115.87% |
| 2018 Q2 | -0.09 EUR | 0.0% |
| 2018 Q1 | -0.09 EUR | 22.42% |
| 2018 FY | - EUR | -18.52% |
| 2018 Q4 | -0.08 EUR | 0.0% |
| 2018 Q3 | -0.08 EUR | 17.19% |
| 2017 FY | - EUR | 80.58% |
| 2017 Q3 | -0.12 EUR | -521.76% |
| 2017 Q4 | -0.12 EUR | 0.0% |
| 2017 Q1 | -0.02 EUR | 93.11% |
| 2017 Q2 | -0.02 EUR | 0.0% |
| 2016 Q2 | -0.41 EUR | 0.0% |
| 2016 Q4 | -0.28 EUR | 0.0% |
| 2016 Q3 | -0.28 EUR | 31.71% |
| 2016 Q1 | -0.41 EUR | -51.85% |
| 2016 FY | - EUR | -39.0% |
| 2015 FY | - EUR | -100.0% |
| 2015 Q1 | -0.23 EUR | -109.09% |
| 2015 Q3 | -0.27 EUR | -17.39% |
| 2015 Q2 | -0.23 EUR | 0.0% |
| 2015 Q4 | -0.27 EUR | 0.0% |
| 2014 Q1 | -0.14 EUR | 0.0% |
| 2014 Q3 | -0.11 EUR | 21.43% |
| 2014 FY | - EUR | 15.25% |
| 2014 Q4 | -0.11 EUR | 0.0% |
| 2014 Q2 | -0.14 EUR | 0.0% |
| 2013 FY | - EUR | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| ABIVAX Société Anonyme | -3.43 EUR | 96.501% |
| Adocia SA | -1.91 EUR | 93.717% |
| Aelis Farma SA | -0.39 EUR | 69.231% |
| Biophytis S.A. | -12.55 EUR | 99.044% |
| Advicenne S.A. | -0.67 EUR | 82.09% |
| genOway Société anonyme | 0.17 EUR | 170.588% |
| IntegraGen SA | -0.03 EUR | -363.32% |
| Medesis Pharma S.A. | -0.80 EUR | 85.0% |
| Neovacs S.A. | -0.00 EUR | -4700.0% |
| NFL Biosciences SA | -0.46 EUR | 73.913% |
| Plant Advanced Technologies SA | 0.07 EUR | 271.429% |
| Quantum Genomics Société Anonyme | -0.09 EUR | -31.868% |
| Sensorion SA | -0.17 EUR | 29.412% |
| Theranexus Société Anonyme | -0.88 EUR | 86.364% |
| TME Pharma N.V. | -1.34 EUR | 91.045% |
| Valbiotis SA | -0.59 EUR | 79.661% |
| TheraVet SA | -0.49 EUR | 75.51% |
| Valerio Therapeutics Société anonyme | -0.15 EUR | 20.0% |
| DBV Technologies S.A. | -0.71 EUR | 83.099% |
| Genfit S.A. | -0.58 EUR | 79.31% |
| GeNeuro SA | -0.59 EUR | 79.661% |
| Innate Pharma S.A. | -0.09 EUR | -27.524% |
| Inventiva S.A. | -2.43 EUR | 95.062% |
| MaaT Pharma SA | -1.73 EUR | 93.064% |
| MedinCell S.A. | -0.88 EUR | 86.364% |
| Nanobiotix S.A. | -1.08 EUR | 88.889% |
| OSE Immunotherapeutics SA | -1.18 EUR | 89.831% |
| Poxel S.A. | -0.91 EUR | 86.813% |
| GenSight Biologics S.A. | -0.54 EUR | 77.778% |
| Transgene SA | -0.22 EUR | 45.455% |
| Valneva SE | -0.73 EUR | 83.562% |